Intellia Therapeutics (NTLA) – CRISPR Pioneer on the Brink of Historic Breakthrough: Stock Explodes Before Crucial Phase 3 Data!

The stock of Intellia Therapeutics is making waves in the markets, surging by more than 30% ahead of a potentially groundbreaking study data update. The trigger is the upcoming release of phase 3 results for the gene therapy Lonvo-z, which could be the first in-vivo CRISPR treatment of its kind. The therapy targets patients with hereditary angioedema and aims to permanently eliminate the cause of the disease through a single gene alteration. Previous study data shows according to company information a reduction in monthly attacks by about...